NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Centessa Pharmaceuticals reported its business highlights and financial results.
Centessa Pharmaceuticals reported a net loss of $36.8 million for the fourth quarter of 2023, with research and development expenses at $29.7 million and general and administrative expenses at $12.3 million. The company's cash, cash equivalents, and short-term investments totaled $256.5 million as of December 31, 2023, expected to fund operations into 2026.
- Registrational PRESent-2 and PRESent-3 studies of SerpinPC for hemophilia B are ongoing, with PRESent-2 advancing toward an interim analysis planned in 2024.
- Clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers is planned in 2024.
- The Phase 1/2a study of LB101 (PD-L1xCD47) for solid tumors is ongoing.
- The company expects cash, cash equivalents and short-term investments will fund operations into 2026.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$6.85M
Forward guidance
Centessa Pharmaceuticals is focused on advancing its key programs and expects to achieve several milestones in the near term.
Tailwinds
- Advancing PRESent-2 study to Part 2 after dose confirmation in 2024.
- Sharing Part 1 data of PRESent-2 study at a medical conference in late 2024 or early 2025.
- Rapidly advancing ORX750 into clinical development after IND clearance.
- Sharing clinical proof-of-concept data for ORX750 in sleep-deprived healthy volunteers in 2024.
- Providing updates on preclinical programs, including follow-up orexin agonists and LB206, as they advance toward clinical studies.
Headwinds
- The company faces risks related to the safety and tolerability profile of its product candidates.
- The company's ability to identify, screen and recruit a sufficient number of subjects in its clinical trials may impact timelines.
- IND-enabling activities for ORX750 and LB206 may face delays.
- Protecting and maintaining the company's intellectual property position poses a risk.
- The company's ability to obtain adequate financing to fund its planned clinical trials and other expenses is subject to risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro